While lipotropic injections may sound like a promising solution for weight loss, its essential to understand that they are not a magical cure
John Buse, Director of the Diabetes Care Center at the University of North Carolina and a principal investigator in GLP-1 outcomes trials, has noted in published commentary that "the antioxidant milieu in type 2 diabetes is genuinely impaired, but whether exogenous supplementation corrects the underlying defect or simply raises circulating levels without tissue impact remains unresolved." [9] That distinction shapes the practical advice: correcting a documented deficiency (measured low whole-blood glutathione in a patient with poorly controlled diabetes) is a different clinical decision from empirically adding glutathione to a well-controlled patient already benefiting from dulaglutide's own oxidative-stress effects
Disruption of this cycle may impair GSH biosynthesis and exacerbate excitotoxic damage, particularly under neuroinflammatory conditions
Darif Y, et al
For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory. Commenting on the topline results, Professor Graham Finlayson, chair in psychobiology at the University of Leeds, said it was striking to see retatrutide reaching the weight loss range historically associated with bariatric surgery and that the headline efficacy results are impressive, particularly the proportion of participants reported to achieve very large weight losses. He added: In principle, that broader pharmacology could produce larger effects on body weight and metabolism, although the full peer-reviewed data will be needed to understand the balance between efficacy, tolerability and discontinuation. While this clinical trial did not examine weight regain after stopping retatrutide, other studies have found that discontinuing weight-loss medications such as semaglutide and liraglutide typically results in near-total weight regain within about 18 months
